Composition and biological significance of the human Nα-terminal acetyltransferases by Starheim, Kristian K et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Proceedings
Open Access Proceedings
Composition and biological significance of the human N-terminal 
acetyltransferases
Kristian K Starheim†1,2,3, Darina Gromyko†1,2,3, Rolf Velde1,2, 
Jan Erik Varhaug2,3 and Thomas Arnesen*1,2,3
Address: 1Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway, 2Department of Surgical Sciences, University of Bergen, 
N-5020 Bergen, Norway and 3Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway
Email: Kristian K Starheim - Kristian.Starheim@mbi.uib.no; Darina Gromyko - Darina.Gromyko@mbi.uib.no; 
Rolf Velde - rolf.velde@student.uib.no; Jan Erik Varhaug - jan.erik.varhaug@helse-bergen.no; Thomas Arnesen* - Thomas.Arnesen@mbi.uib.no
* Corresponding author    †Equal contributors
Abstract
Protein N-terminal acetylation is one of the most common protein modifications in eukaryotic
cells, occurring on approximately 80% of soluble human proteins. An increasing number of studies
links N-terminal acetylation to cell differentiation, cell cycle, cell survival, and cancer. Thus, N-
terminal acetylation is an essential modification for normal cell function in humans. Still, little is
known about the functional role of N-terminal acetylation. Recently, the three major human N-
acetyltransferase complexes, hNatA, hNatB and hNatC, were identified and characterized. We
here summarize the identified N-terminal acetyltransferase complexes in humans, and we review
the biological studies on N-terminal acetylation in humans and other higher eukaryotes.
Background
The importance of N-terminal acetylation in human cell
biology and disease has been increasingly recognized.
During the last five years, the major human N-acetyl-
transferase complexes (NAT) have been identified and
characterized. In humans as in yeast, three NAT com-
plexes are believed to perform most N-acetylations,
namely the human NatA, NatB and NatC complexes
(hNatA, hNatB, and hNatC) [1-4]. In addition, a potential
hNatE complex has been described [5-7]. A number of
studies have described various aspects of N-terminal
acetylation in humans, such as substrates, NAT knock-
down phenotypes, and expression patterns of NAT subu-
nits. Through these studies, a complex and specific system
of N-terminal acetylation has been revealed. This system
is to a large extent conserved from yeast. Still, little is
known about the function and regulation of the system,
and of the specific mechanisms through which pheno-
types are mediated. In this review we give a comprehen-
sive overview of the knowledge of co-translational N-
terminal acetylation in humans and other higher eukary-
otes.
The human NatA complex
The NatA complex is the most thoroughly studied of the
three major NAT complexes in higher eukaryotes. The
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NatA complex is believed to be the major NAT complex
both in humans and in yeast: the number of potential
hNatA substrates is high as compared to human NatB and
human NatC (hNatB and hNatC). Also, the phenotypes
resulting from hNatA knockdown appears to be slightly
more severe than those observed for hNatB and hNatC
knockdown [3,4,8].
Composition of the hNatA complex
The hNatA complex is conserved from yeast with respect
to subunit homology [1] and substrate specificity [9]. The
most characterized human hNatA complex consists of the
catalytic subunit hNaa10p (hArd1), and the auxiliary sub-
unit hNaa15p (NATH/hNat1) [1,2,10]. They are ortho-
logues of the yeast NatA components yNaa10p and
yNaa15p. Both hNaa10p and hNaa15p are associated
with ribosomes, suggesting a model where hNatA per-
forms co-translational acetylation of nascent polypeptides
[1]. Interestingly, a significant portion of hNaa10p and
hNaa15p is also found to be non-ribosomal. Paralogues
of hNaa10p, hNaa11p (hArd2), and of hNaa15p,
hNaa16p (hNat2), have been suggested to participate in
functional hNatA complexes [11,12]. This allows for four
possible hNatA complexes, resulting in a more complex
subunit composition in humans as compared to yeast
(Figure 1). Based on expression sequence tag data (EST)
from UniGene Cluster, and experimental evidence [12],
we here describe hNaa10p and hNaa15p as components
of the abundant form of the hNatA complex, and
hNat11p and hNat16p as alternative and less abundant
subunits in the hNatA complex (Figure 1).
hNaa10p
hNaa10p (hArd1) is a 235 amino acid protein with a the-
oretical mass of 25.4 kDa. It contains a conserved core
motif responsible for acetyl coenzyme A binding (Q/
RxxGxG/A), as found in all members of the GNAT super-
family of N-acetyltransferases (GNAT, Pfam: PF00583
Acetyltransf_1). hNaa10p is homologous to the yeast
NatA catalytic subunit yNaa10p. It localizes to both the
cytoplasm and the nucleus, and it is present both in a
ribosome-bound and a non-ribosome-bound form [1].
The C-terminal part of hNaa10p is unstructured [13] con-
taining several potential phosphorylation sites. Indeed,
hNaa10p is phosphorylated on several of these sites
[14,15]. At least some of the phosphorylations are medi-
ated through the GSK-3 kinase [16]. This may point
toward regulation of hNatA activity through phosphoryla-
tion of hNaa10p.
Mammalian Naa10p has several splice variants that are of
biological interest. Studies on M. musculus have identified
an evolutionarily conserved NatA complex, consisting of
mNaa10p (mArd1) and mNaa15p (mNat1) [17]. Three
splice variants were identified for mNaa10p (mArd1):
mNaa10p198, mNaa10p225, and mNaa10p235, where
mNaa10p235  was considered as the wildtype [18].
mNaa10p225  and mNaa10p235  displayed differences in
subcellular localizations, suggesting that they may differ
in activity and function [19]. While mNaa10p235 is a com-
ponent of the mNatA complex together with mNaa15p,
mNaa10p225 was shown to N-acetylate a lysine residue of
transcription factor hypoxia-inducible factor 1 (HIF-1),
Composition of the four different hNatA complexes Figure 1
Composition of the four different hNatA complexes. The hNatA subunits hNaa10p, hNaa11p, hNaa15p and hNaa16p 
can combine to form four variants of the hNatA complex. All subunits tested bind to ribosomes (hNaa11p not tested yet), sug-
gesting that all four variants can acetylate nascent polypeptides (e.g polypeptide with an N-terminal Serine) co-translationally. 
The gradient illustrates the expected abundance of the various complexes. Based on EST data and immunoprecipitation exper-
iments [21], hNaa10p-hNaa15p forms the most abundant version of the complex, displaying a stochiometric relationship of 6:1 
compared to the hNaa10p-hNaa16p complex in HEK293 cells. The hNaa11p-hNaa15p and hNaa11p-hNaa16p complexes are 
probably present to an even lesser extent in most tissues, except for tissues like testis, where hNaa11p is upregulated. In the 
lower part of the figure it is indicated which experimental data that forms the evidence of the complex formations. IP, immuno-
precipitation; MS, Mass Spectrometry; WB, Western Blotting.
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and thereby destabilize the protein [20]. The mammalian
Naa10p variants mNaa10p235 and hNaa10p235 did not
destabilize HIF-1 [18]. In humans, only one isoform of
hNaa10p have been characterized: the wildtype
hNaa10p235, which is orthologous to mNaa10p235 [19].
EST data show that hNAA10 (ref. no. Hs. 433291) is ubiq-
uitously expressed in most tissues. Northern blot analysis
of multiple human tissues showed hNAA10 expression in
all studied tissues, with higher expression levels in brain,
heart, liver, and skeletal muscle [20]. Several groups dem-
onstrated hNaa10p expression at protein level in a broad
range of human cancer cell lines, and also in human tis-
sues [21,22].
hNaa11p
hNaa11p (hArd2) display 81% sequence identity to
hNaa10p, and hNAA11 is the result of a mammal-specific
retrotransposition event, making hNAA11 a gene dupli-
cate of hNAA10. Exogenous hNaa11p displays N-acetyl-
transferase activity and forms putative hNatA complexes
in association with hNaa15p and hNaa16p [11,12]. The
hNAA11 mRNA is moderately expressed in most tissues,
and its function is largely unknown. In NB4 cells it was
found that levels of hNaa10p and hNaa15p decreased
during retinoic acid induced differention, while the level
of hNaa11p remained stable [11], thus some difference in
function may be expected between the proteins.
EST data show that hNAA11 expression is restricted to cer-
tain tissues (liver, placenta, skin, testis). Study of hNAA11
expression in human cell lines indicated expression in dif-
ferent human epithelial cells and promyelocytic leukemia
cells. These levels were significantly lower than those
observed for hNAA10 [11]. Recently, Pang and colleagues
reported that the mouse orthologue of hNAA11, mouse
NAA11 (mNAA11, mARD2) was upregulated in testis dur-
ing male meiosis [23]. It was not found upregulated in
other somatic tissues, except for trace amount in the
ovary. Interestingly, the testis developmental expression
pattern of mNaa11p clearly indicated delayed translation
of mNAA11  during spermatogenesis. This may be
explained by a tissue specific role of mNaa11p at a later
stage of the spermatogenic process, and a regulated role of
mNAA11 different from that of mNAA10. As mNAA10 is
located on the X-chromosome, the authors speculated
that the increased mNAA11 expression is to compensate
for the loss of mNAA10 expression during meiosis.
hNaa15p
The auxiliary subunit hNaa15p (NATH, hNat1) is a pro-
tein with a theoretical mass of 101.3 kDa. It is localized to
the cytoplasm, where it interacts with both cytosolic and,
in particular, cytoskeleton-bound polysomes [1]. Also, a
large fraction of hNaa10p and hNaa15p are not ribos-
ome-associated. This may indicate that the subunits can
have roles other than those in a NatA complex. hNaa15p
expression levels are positively correlated with hNaa10p
expression levels in vivo. [24]. Observations in yeast [24]
and in human cell culture [8,25] could point to hNaa15p
positively affecting the level of hNaa10p.
hNAA15 is expressed in most adult human tissues at a low
level. Various studies have shown that the expression of
hNAA15 is correlated with high proliferation. Increased
expression have been detected in highly proliferative tis-
sues and cell lines such as Burkitt lymphoma cell line,
colorectal carcinoma SW480 cell lines, testis, ovary,
spleen, colon and stomach [10,26]. However, exogenous
overexpression of hNAA15 in NPA and HEK293 cell lines
did not alter cellular proliferation per se [10].
A series of studies has focused on the role of the mouse
NAA15  splice variant Tubedown-1  (Tbdn-1) in develop-
ment and differentiation, and the expression of mNaa15
(Narg1, Tbdb100) in neuronal development. As the
sequence similarity beween human and mouse Naa10p
and Naa15p is very high (99.2% and 99.7%, respectively),
one might expect that results from mouse studies are
highly relevant also for human systems. Tbdn-1 encodes a
protein of 593 amino acids. This is considerably shorter
than the 866 amino acids of hNaa15p. Both Tbdn-1 and
mNAA10 were identified as embryonic genes that were
expressed in vivo at relatively high levels in neural precur-
sors, and downregulated during neuronal development.
The same tendency was found for mNAA15 in vitro in the
mouse embryonic carcinoma P19 [17] and in mouse
embryonic cell line (IEM) [27] when differentiation was
induced. High expression of mNAA15  and mNAA10
remains in postnatal period at the sites of neurogenesis
and synaptic plasticity like hippocampus and cerebellar
cortex [17]. These findings suggest that a high expres-
sional rate of mNatA may be a marker for immature cells
being able to divide, or to undergo long term changes in
formation of synapses. Also, Ohkawa and colleagues stud-
ied mNAA15 and mNAA10 expression postnatally in the
cerebellum of developing neurons. They found increasing
expression levels of mNAA15  and mNAA10  during
Purkinje cell development. This could be an indication
that N-acetyltransferase activity of mNatA is linked to
processes such as dendrogenesis and dendritic arborisa-
tion [28].
Endothelial-specific conditional knockdown of mNAA15
in bitransgenic mice led to neovascular rethinopathy [29].
These data are in accordance with findings that mNAA15
expression is suppressed both during oxygen-induced
retinopathy in mice and during retinopathy of prematu-
rity in humans [30], and in neovascular retinopathy asso-BMC Proceedings 2009, 3(Suppl 6):S3 http://www.biomedcentral.com/1753-6561/3/S6/S3
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ciated with diabetes [27]. This may indicate that
maintenance of mNAA15 is important both for retinal
blood vessel homeostasis, and for preventing retinal neo-
vascularization in adults.
Northern blot analysis of mNAA15 clearly demonstrated
different distribution of gene expression in tissues and
during development. In adult tissues mNAA15 level was
relatively low, with exception of the atrial endocardium,
the endothelial and myeloid regions of bone marrow, and
in vascular bed of ovarian follicles [27]. These data indi-
cate that mNAA15 may be involved in regulation of vas-
cular and hematopoietic development, and physiological
angiogenesis. Knockdown of mNAA15  in endothelial
cells led to significant increase in cellular permeability,
and knockdown in vivo in mice resulted in retinal neovas-
cularization with formation of abnormal blood vessels
prone to albumin leakage. Since mNaa15p was shown to
interact with cortactin, a known regulator of cellular per-
meability, the observed mNAA15 RNAi phenotype was
suggested to be due to impaired interactions between cort-
actin and mNaa15p. mNaa15p was also proposed to be a
cortactin-associated controller of the retinal endothelial
cells permeability to albumin [25].
The increased expression of mNAA15 and mNAA10 that
was observed during postnatal dendrogenesis could be
due to an essential role for N-acetyltransferase activity in
normal dendritic development. Interestingly, knocking
down rat NAA10, or overexpressing the dominant nega-
tive forms of NAA10 dramatically limited dendrogenesis
in cultured rat embryonic neurons. These data indicate
that NatA positively regulates the growth and branching
of dendritic extensions, this being necessary for retaining
the plasticity of synapsis formation [28].
When differentiation of human neuroblastoma cells was
induced by retinoic acid treatment in vitro, a significant
decrease in hNaa15p expression was observed. This is in
agreement with pattern of hNaa15p expression in neurob-
lastic tumors [31].
When differentiation of human NB4 promyelocytic leuke-
mia cells was induced by retinoic acid, endogenous
hNaa10p and hNaa15p was downregulated, while the
hNaa11p level remained unchanged [11]. This differenti-
ation pattern is in accordance with recently reported data
from studies on mouse testis, and it is a strong argument
for separate regulatory mechanisms of hNaa10p and
hNaa11p during differentiation [23].
hNaa15p (Tbdn100) was also proposed to be an essential
part of a Ku-transcriptional complex along with Ku70 and
Ku80 [32]. This complex regulates osteocalcin gene
expression in human osteosarcoma cells. Chromatin
immunoprecipitation experiments confirmed that both
Ku and hNaa15p were associated with the Osteocalcin
promoter. This study implicated hNaa15 in a nuclear
function, perhaps independent of hNaa10p and N-ter-
minal acetylation.
hNaa16p
An orthologue of hNaa15p, hNaa16p (hNat2) was
recently described. It displays 70% sequence identity to
hNaa15p, and the hNAA16 gene originates from an early
vertebrate duplication event from the common ancestor
of hNAA15 and hNAA16. As of today, the specific func-
tion of hNaa16p remains unknown [12]
Endogenous hNaa16p is found to interact with hNaa10p,
and an exogenous complex between these two proteins is
functional as an hNatA enzyme complex. Also, hNaa16p
is found in both a ribosome-bound form and a non-ribos-
omal form in human cells, thus it may be a component of
a co-translational hNatA complex.
EST data show that hNAA16  (ref. no. Hs. 512914) is
expressed in a variety of human cell lines, but generally at
lower levels as compared to hNAA15  (ref. no. Hs.
715706). hNAA16 expression have not been correlated
with cell proliferation, as was observed for hNAA15 [12].
When comparing the expression of hNAA15 and hNAA16,
hNAA15 seems to be the dominant variant in most tissues
and cell types. For example, in HEK293 cells hNAA15 and
hNAA16 are expressed in a 5:1 ratio at the mRNA level,
and the resulting proteins are detected in complex with
hNaa10p in a 6:1 ratio, respectively. Exceptions from this
are tissues like adrenal gland, mammary gland, heart, tes-
tis, and thymus, where hNAA16 appears to be the domi-
nant variant [12]. Expression patterns in mouse tissues
also demonstrated that mNAA15 is the dominating spe-
cies as compared to mNAA16 [17].
hNatA acetylates a wide range of substrates involved in 
important cellular functions
The human NatA complex (hNatA) is coupled to removal
of the initial methionine by Methionine aminopeptidase
1 and 2. Once the methionine is removed, the resulting N-
terminus is available for acetylation by hNatA. The hNatA
complex potentially acetylates Ser-, Ala-, Thr-, Gly-, Val-
and Cys- N-termini. A recent proteomics study identified
a large number of hNatA substrates, and the in vivo sub-
strate specificity of hNatA was found to closely resemble
that of yNatA [9]. The COFRADIC methology used in this
study is presented elsewhere in this supplement (Van
Damme et al.). This study detected proteins displaying sig-
nificantly altered N-acetylation after downregulation of
both hNaa10p and hNaa15p in human cell culture [9].
The list of proteins was surprisingly short: only 17 pro-
teins among several hundred acetylated hNatA type sub-BMC Proceedings 2009, 3(Suppl 6):S3 http://www.biomedcentral.com/1753-6561/3/S6/S3
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strates analyzed showed a significant change in
acetylation status. Most likely, the temporary knockdown
of hNatA only partially affected some of the substrates,
while the bulk of substrates were unaffected. Among
affected substrates were proteins participating in protein-
protein interactions (Ankyrin repeat domain-containin
protein 44, WD-repeat protein 5), transcriptional regula-
tion (Transcriptor elongation factor B, GCN1-like protein
1, density regulated protein), ribosome assembly (ribos-
omal protein L13a), protein folding (Cyclophilin A), RNA
maturation (U6 snRNA-assosiated Sm-like protein
LSm8), and protein modification (SAPK substrate protein
1, Ubiquitin-like 1-activating enzyme E1A). We hypothe-
size that N-acetylation may be important for substrate
function, and that a decrease in N-acetylation of some of
these or undetected substrate proteins may induce the
observed phenotypes associated with hNatA knockdown.
Obviously, several important hNatA substrates are likely
to be present in the pool of proteins unaffected by hNatA
knockdown, but since complete removal of hNatA
appears to be equivalent to cell death (see separate section
below), these will be hard to detect by this methodology.
Based on the substrate specificity and the N-terminal
sequences of all known human proteins (SwissProt v.
56.0), it was estimated that more than 8000 unique
human proteins (out of a total of around 20,000 unique
proteins) are hNatA substrates [9].
There are some examples of possible downstream NatA
substrates or effectors where a direct link has not been
established, but where the biological importance makes it
worth mentioning. These include hemoglobin subunits -
globin and -globin, -amyolid precursor protein (APP),
-tubulin, -catenin and HIF-1.
The hemoglobin subunits -globin and -globin are
potential hNatA substrates due to their N-terminal
sequences matching the hNatA substrate specificity. N-
terminal acetylation of these proteins leads to decreased
O2-binding [33,34].
Through the interaction of hNaa10p with APP, hNatA
may be linked to Alzheimers disease. The hNatA complex
hNaa10p-hNaa15p could suppress the secretion of a proc-
essed form of APP, amyloid -protein (A) in mouse neu-
roblastoma cell line. A is a main component of the
pathological state that brings about Alzheimers disease.
The finding that secretion of A could be modulated by
hNatA is interesting, but the mechanism is completely
unknown. Although APP is a direct interactor of
hNaa10p, its N-terminal sequence (MLPG) is unsuited as
an hNatA substrate. Thus, it is still unclear if hNatA mod-
ulates A secretion direct or indirect through N-acetyla-
tion of one or more components of the A secretion
pathway, or if the effect is mediated through the direct
interaction with APP [2].
NatA has been linked to dendritic growth in developing
neurons. -tubulin was proposed to be an hNatA sub-
strate, and the effect on dendritic growth was shown to be
mediated through the acetylation of -tubulin. The N-ter-
minus of -tubulin (MRECI) does not match the
hNaa10p substrate specificity, and the authors suggested
that hNatA N-acetylates  -tubulin post-translationally
[28]. This may indicate that Naa10p could act both as a
NAT with N-acetyltransferase activity, and as a HAT (His-
tone Acetyltransferase) with N-acetyltransferase activity.
However, there is no evidence for this at present.
Indeed, hNaa10p has been suggested to act as an N-
acetyltransferase also in other studies. Recently, hNaa10p
was shown to acetylate and activate -catenin in lung can-
cer cells, thereby promoting cell proliferation [35]. -cat-
enin has become an attractive target for studies due to its
multiple roles in cancerogenesis, development and regen-
eration. It is an integral component of the Wnt signalling
pathway, and in conjunction with T-cell factor 4 (TCF4) it
functions as a transcriptor factor complex for many genes.
Another field of interest, with respect to the possible N-
acetylation activity of hNaa10p, is the interaction between
hNaa10p and hypoxia-inducible factor 1 (HIF-1).
hNaa10p (hNaa10p235) stably interacts with HIF-1 [36],
but hNaa10p does not acetylate HIF-1 [22,36-38]. By
binding with hNaa10p, HIF-1 inhibits hNaa10p-medi-
ated activation of -catenin/TCF4 complex, leading to
repression of -catenin transcriptional activity [39].
Thereby, a new mechanism was proposed, where an
hNaa10p-HIF-1 interaction inhibits Wnt signaling, lead-
ing to hypoxia-induced growth arrest in tumors. Gene
expression analysis of hNAA10 RNAi-treated HepG2 cells
with hypoxia-treated samples showed overlap between
hNAA10-regulated genes and hypoxia-regulated genes
[37], strengthening the hypothesis that hNaa10p and HIF-
1 may work in concert. More detailed information
regarding this has previously been presented [40].
As we know of, no convincing proof has been given as to
whether hNaa10p can perform N-acetylation  in vivo.
Future studies are needed to reveal whether hNaa10p in
fact have a dual function as both a NAT and a HAT type of
enzyme, or whether hNaa10p indirectly mediate N-
acetylation.
Knockdown studies point to a role for hNatA in cell cycle 
and apoptosis
A general function of the hNatA complex has not been
assessed, but knockdown studies have pointed to some
important cellular processes that are affected by hNatA.BMC Proceedings 2009, 3(Suppl 6):S3 http://www.biomedcentral.com/1753-6561/3/S6/S3
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Figure 2 gives an overview of phenotyphes after hNAA10
knockdown.
Knockdown of hNAA10 in HepG2 cells gave suppression
of genes involved in cell growth and survival (BECN1,
antiapoptotic protein beclin, and the TPD52 marker of
cell proliferation), and metabolism. Among the mostly
upregulated genes were antiproliferative gens such as BIK
(negative regulator of cell growth), and a group of extra-
cellular matrix genes [37]. In addition, several genes
involved in cell cycle, growth, and survival were positively
regulated as a response to hNAA10 overexpression: CDC2
(cell division cycle 2), CCNA2  (Cyclin A2) and BIRC5
(apoptosis inhibitor surviving) [37].
Lim and colleagues found that hNAA10 RNAi in human
lung cancer cells H1299 and A549 inhibited cell prolifer-
ation and arrested cells in the G1-phase. Cyclin D1 was
also suppressed in growth-arrested cells. This was con-
nected to repressed promoter activity of CCND1 gene. It
was shown that binding of the -catenin/TCF4 transcrip-
tion factor complex to the CCND1 promoter was posi-
tively regulated by hNaa10p, and negatively regulated
after hNAA10 RNAi downregulation [35]. These data sug-
gest that hNaa10p promotes proliferation of lung cancer
cells through the -catenin pathway.
In HeLa cells, knockdown of hNAA10, hNAA15  and
hNAA16 induced apoptosis through the caspase depend-
ent pathway, and possibly through G0/G1 cell cycle arrest
[8,12]. In HeLa S3 cells, knockdown hNAA10 did not lead
to apoptosis, but induced G0/G1 cell cycle arrest and sen-
sitization to daunorubicin-induced apoptosis [8]. On the
other hand, it was reported that hNaa10p have a proapop-
totic function in DNA-damage induced apoptosis by
working as a caspase modulator. Drosophila NAA10 was
found among genes involved in caspase-dependent cell
death after prolonged doxorubicin treatment of Drosophila
Kc cells [41]. In contrast to the results from Arnesen and
colleagues, the viability of HeLa cells was not affected by
hNAA10 RNAi treatment. Furthermore, cells turned to be
less prone to apoptosis under doxorubicin treatment [41].
More experimental evidence is needed to clear up these
phenotypic differences. Finding and verification of
hNaa10p specific substrates related to apoptosis will also
be of great value.
In conclusion, hNatA plays an important role in cell cycle
and cell growth. Loss of hNatA activity leads to decreased
cell viability, and in many cases, apoptosis (Figure 2).
During apoptosis, both hNaa10p and hNaa15p are
cleaved, presumably by caspases, resulting in decreased
NatA activity [1]. Knockdown studies of hNAA10,
hNAA15 and hNAA16 in human cells did not show com-
pensatory expression of corresponding paralogs hNAA11,
hNAA15 and hNAA16, thereby suggesting independent
regulation of these genes [12,37].
Expression of hNAA10 and hNAA15 is correlated with 
tumor development
hNAA10 and hNAA15 expression levels are higher in sev-
eral types of tumors. Indeed, several studies have shown
that hNAA10  and hNAA15  expression correlates with
aggressiveness of tumors. This is consistent with the
above-mentioned correlation between hNAA10  and
hNAA15 expression and cell proliferation.
hNAA10 was significantly overexpressed in hepatocellular
carcinomas. In the same study hNAA10  was identified
among genes associated with dedifferentiation of hepato-
cellular carcinoma [42]. By immunohistochemistry,
hNaa10p was shown to be overexpressed in colorectal
cancers as compared to adjacent normal tissue [43]. An
other study demonstrated that hNaa10p was overex-
pressed in colorectal cancers as well as in breast cancers
[44]. The hNat10p upregulation was especially significant
in cells with epithelial origin. Comparison studies on
glandular carcinomas and squamous carcinomas originat-
ing from the same tissue concluded that the high positive
rate of hNaa10p expression was lower in glandular carci-
noma than in squamous cancer [44].
Knockdown of hNAA10 of the hNatA complex leads to apop- tosis and cell cycle arrest Figure 2
Knockdown of hNAA10 of the hNatA complex leads 
to apoptosis and cell cycle arrest. Knockdown of 
hNAA10 leads to reduced acetylation of hNaa10p subtrates 
[9]. As a direct or indirect effect of this, apoptosis and cell 
cycle arrest is observed [8]. Direct acetylation of -catenin 
has been implicated in the cell cycle arrest mediated by 
hNAA10 knockdown [35]. Loss of acetylation can lead to 
reduced Cyclin D1 expression, and subsequent cell cycle 
arrest in the in the G0-G1 phase. One hypothetical mecha-
nism is that hNatA affects cell cycle indirectly via a HAT (His-
tone Acetyltransferase), acting on -catenin or directly or 
indirectly at the level of Cyclin D1 expression. This is more 
thoroughly issued in a previous publication [40]. More exper-
imental studies are needed to determine the mechanisms 
through which hNatA knockdown phenotypes are formed.
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hNAA15 was originally identified as a gene overexpressed
in gastric cancer [26] and papillary thyroid carcinomas,
especially in clinically aggressive tumors with histological
evidence of poorly differentiated or dedifferentiated areas
[10]. hNaa15p expression levels were also higher in thy-
roid neoplasms (follicular adenomas and papillary thy-
roid carcinomas) [21]. High levels of hNaa15p protein
expression were observed in neuroblastomas, with unfa-
vourable histopathology and advanced stage. Further-
more, the expression level of hNaa15p was found to
correlate with high-risk groups and poor outcome [31].
When comparing the mRNA expression of hNAA15 and
hNAA16 in thyroid cell lines from normal fetal and adult
thyroid cells; follicular, papillar and anaplastic thyroid
carcinomas, hNAA15  was found to be slightly overex-
pressed in all thyroid cancer cell lines compared to expres-
sion in primary thyroid cell lines. No similar
overexpression was observed for hNAA16 [12].
Taken together, the hNatA subunits seem to play impor-
tant roles in cell proliferation and potentially in tumori-
genesis. They may be important biomarkers for various
forms for cancers. hNatA subunits can also be potential
targets for cancer drug treatment, as previously summa-
rized by Arnesen and colleagues [40]. To better under-
stand in which processes hNatA participate, it would be of
utmost importance both to establish functional links
from specific hNatA substrates to cellular mechanisms,
and to understand the complete cellular effect of hNatA
acetylation.
The human NatB complex
The human NatB complex (hNatB) was recently identified
[3,45]. It is composed of the catalytic subunit hNaa20p
(hNAT3), and the auxiliary subunit hNaa25p (hMDM20).
This complex is conserved from yeast both with respect to
subunit composition and substrate specificity.
Both subunits are found in the cytoplasm, where they are
present both in a ribosome-bound and a non-ribosomal
form. The substantial amount of hNaa20p and hNaa25p
present in the non-polyribosomal fraction indicates that
these proteins dynamically interact with the ribosome
and/or have other functions independent of ribosome
binding [3].
Composition of the hNatB complex
hNaa20p
hNaa20p has a theoretical molecular mass of 20.4 kDa,
and contains a conserved acetyltransferase domain.
hNaa20p localizes to both cytoplasm and nucleus, and it
is homologous to the yeast NatB catalytic subunit
yNaa20p [3].
hNaa25p
hNaa25p has a theoretical molecular mass of 112.3 kDa.
It has been predicted to contain two globular domains, a
TPR-region, and a nuclear localization signal. Even so,
hNaa25p has a cytoplasmic localization, and it has not
been observed in the nucleus. The hNaa25p protein
shares 20.4% and 92.9% sequence identity with its yeast
and mouse homologues, respectively, indicating a high
degree of evolutionary conservation within higher eukary-
otes, and a moderate degree of sequence conservation
from yeast to human [3].
Substrates of hNatB
The hNatB complex was found to in vitro acetylate a pep-
tide with an MDEL N-terminus [3]. This represents the N-
terminus of the NF-B subunit p65. p65 is also in vivo
acetylated in HeLa cells [9]. Indeed, the identification of
many acetylated Met-acidic N-termini in a large scale pro-
teomics analysis [9], including the MDEL N-terminus,
suggest that this activity is dependent on the hNatB com-
plex. As the yNatB is known to acetylate methionines that
are followed by an acidic residue, the acetylation of the
MDEL-peptide supports a conservation of substrate spe-
cificity of NatB from yeast to man [46].
Knockdown of hNatB induces cell cycle arrest
Knockdown of hNatB subunits inhibits cell growth and
proliferation, and disturbs cell cycle progression. Knock-
down of hNAA20 leads to G0/G1 arrest, and an increase in
the level of p21 (as summarized in Figure 3). Knockdown
of hNAA25 leads to cell death, a decrease in G0/G1 cells,
and a decrease in p21 levels. Also, a decrease in hNaa20p
levels was observed after hNAA25 knockdown, indicating
that hNaa25p is needed for hNaa20p stability [3]. This
also implicates that hNAA25  phenotypes will include
Knockdown of hNAA20 of the hNatB complex leads to inhi- bition of growth and cell cycle arrest Figure 3
Knockdown of hNAA20 of the hNatB complex leads 
to inhibition of growth and cell cycle arrest. Knock-
down of hNAA20 may lead to reduced acetylation of 
hNaa20p substrates. As a direct or indirect effect of this, 
inhibition of cell growth, and G0-G1 cell cycle arrest is 
observed. The finding that p21 is upregulated after hNAA20 
knockdown suggest a mechanism where loss of hNaa20p 
mediated acetylation leads to p21-mediated cell cycle arrest.
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hNAA20 phenotypes. The change in p21 levels indicate
that at least some of the effects of hNatB knockdown are
mediated through p21, which is a known inhibitor of
traverse through the G1-phase [47]. The seemingly contra-
dictory effects of hNAA20 and hNAA25 knockdown can
be the result of complex downstream mechanisms for the
hNatB. Elevated levels of p21 may inhibit the induction of
apoptosis while in some cases it is known that preventing
induction of p21 is necessary to induce apoptosis [48].
Thus, the p21 level may explain why we detect cell death
when analysing the hNAA25 knockdown cells, while no
significant levels of apoptosis are detected for hNAA20
knockdown cells. The differences in phenotypes could
also indicate that one or both hNatB subunits may have
individual functions in addition to those of the hNaa20p-
hNaa25p complex. The observation that hNAA20 knock-
down leads to cell cycle arrest was also confirmed in other
studies [45]. Further information regarding hNatB can be
found elsewhere in this supplement [49].
The human NatC complex
The human NatC complex (hNatC) was recently
described. It consists of the catalytic subunit hNaa30p
(hMak3), and the auxiliary subunits hNaa35p (hMak10)
and hNaa38p (hMak31) [4].
hNatC is conserved from yeast to man both with respect
to subunit composition, and substrate specificity, as is
also the case with hNatA and hNatB. hNaa30p and
hNaa35p localize almost exclusively to the cytoplasm
while hNaa38p also localizes to the nucleus. In the cyto-
plasm, all three subunits are found both in a ribosome-
bound and a non-ribosomal form. This supports a model
where the hNatC complex co-translationally acetylates
nascent polypeptides. As the subunits are present also in a
non-ribosome-bound form, they may dynamically inter-
act with ribosomes, and/or have functions independent of
ribosomal binding as also suggested for the hNatA and
hNatB subunits [4].
Composition of the hNatC complex
hNaa30p
The N-acetyltransferase hNaa30p (hMak3) (GeneID
122830) is a protein with theoretical molecular weight of
39.3 kDa. hNaa30p acetylates peptides with N-termini
MLALI, MLGTG and MLGTE [4]. This substrate specificity
is similar to that observed for yNaa30p, thus Naa30p is
evolutionary conserved in eukaryotes. Also, these in vitro
experiments showed that hNaa30p was enzymatically
active without being associated with hNaa35p and
hNaa38p, showing that the substrate specificity of hNatC
is at least partly contained within the catalytic subunit
itself. Pesaresi and co-workers demonstrated that the A.
thaliana Naa30p (AtNat30p) alone was able to function-
ally replace the yeast NatC complex. Also, in contrast to
AtNaa30p, knockout of AtNaa35p alone did not result in
any obvious defects [50]. This indicates that Naa30p may
have functions independently of the NatC complex in
higher organisms than yeast.
Interestingly, hNaa30p (362 amino acids) is considerably
larger than its yeast homolog (176 amino acids). This is
mainly due to an additional N-terminal region of
hNaa30p. Similarly, the A. thaliana Naa30p also contains
additional residues as compared to yeast Naa30p, and
AtNaa30p displayed enzymatic activity independently of
AtNaa35p [50]. The function of this N-terminal domain
hNaa30p domain is unclear, but it contains several poten-
tial phosphorylation sites, making it a possible region for
posttranslational regulation of hNaa30p activity, as was
observed for hNaa10p [16].
hNaa35p
hNaa35p (hMak10) is the human homologue of the yeast
NatC subunit yNaa35p (yMak10p). The experimentally
described hNAA35 differed from the predicted sequence
available at Entrez in that a splice event had taken place
resulting in the loss of nucleotides 1465–1704 as com-
pared to the predicted sequence [4].
The rat NAA35 homologue was identified as a novel gene
upregulated in the healing corneal epithelium. Its expres-
sion correlated with reepithelialization of cornea and
maturation of the cornea and skin suggesting the role of
this gene in epithelial development, differentiation, and
wound healing [51].
hNaa38p
hNaa38p (hMak31, LSMD1) is the human homologue of
yeast NatC subunit yNaa38p (yMak31p). hNaa38p is a
member of the Sm and Sm-like proteins which associate
with RNA and are involved in RNA-processing event. As
hNaa38p is also found in the nucleus, it may have a
nuclear role in RNA processing independent of the hNatC
complex [4]. It is puzzling why an Sm-like protein is a part
of the NatC complex. One could picture a model where
the RNA-binding capacities of hNaa38p participate in the
interaction between the NatC complex and factors in the
translation process. An interesting question in such a sce-
nario is why only the hNatC complex contains this factor
(or indeed, why the three NAT complexes differ in their
auxiliary subunits). Do the auxiliary subunits of the NAT
complexes mediate complex-specific anchoring to the
ribosome? The question of how the NATs are associated
with the ribosome is exciting. Answering this will be
important to fully understand how N-terminal acetyla-
tion is facilitated.BMC Proceedings 2009, 3(Suppl 6):S3 http://www.biomedcentral.com/1753-6561/3/S6/S3
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hNatC substrates
N-terminal acetylation and myristoylation facilitate
membrane association for several types of GTPases [52]. It
was recently shown that the human Arf-like GTPase Arl8b
(hArl8b) depended on its acetylated N-terminus for
proper lysosomal association [53]. The N-terminal
sequence of hArl8b is MLAL, matching the substrate spe-
cificity of the NatC complex from yeast: methionine fol-
lowed by a hydrophobic amino acid residue [7]. Thus,
hArl8b is a potential hNatC substrate. Indeed hNaa30p
acetylates an MLAL N-terminus in vitro. Also, hNAA30
knockdown leads to aberrant lysosomal targeting of
hArl8b [4]. This points to a direct link between hNatC
mediated N-terminal acetylation and proper functional
localization of hArl8b. Another human protein of which
the acetylation of the N-terminus by hNatC may be func-
tionally important is the human GTPase Arf-related pro-
tein 1 (ARFRP1). ARFRP1 depends on its N-terminal
acetylation for proper Golgi association and its N-termi-
nus matches NatC substrate requirements [54].
Another important potential hNatC substrate is the pro-
tein kinase mammalian Target Of Rapamycin (mTOR).
Wenzlau and colleagues found that knockdown of
zNAA35 leads to loss of phosphorylation of downstream
mTOR substrates. Pharmacological inhibition of TOR
with rapamycin showed similar phenotypes as zNAA35
mutants with respect to growth and vessel defects [55],
thus defects in the TOR pathway may partly explain the
NAA35 knockout phenotypes.
Expression of the hNatC subunits
EST data from UniGene Cluster indicate that hNAA30
(Hs. 165465), hNAA35 (Hs. 436098), and hNAA38 (Hs.
565094) are ubiquitously expressed in epithelial tissue,
loose and dense connective tissue, and in muscle and
nervous tissues. hNAA30, hNAA35  and hNAA38  are
found co-expressed in tissues, suggesting that expression
is due to hNatC function. An exception is the pituitary
gland, where hNAA35 and hNAA38, but not hNAA30, are
significantly expressed. One may speculate if hNaa35p
and hNaa38p have functions independent of hNaa30p in
the pituitary gland. Gene expression of hNAA30  and
hNAA35  at mRNA level measured by RT-qPCR is in
accordance with EST data, confirming ubiquitous expres-
sion of these genes in all analyzed human cancer cell lines
(Gromyko D. et al., unpublished data).
Knockdown of hNatC induces apoptosis in human cell 
lines
Knockdown of each of the hNatC subunits leads to similar
phenotypes in HeLa cells: reduced cell proliferation and
apoptosis [4]. This suggests that the observed knockdown
phenotypes indeed are due to the loss of hNatC activity,
and that all three subunits are needed for hNatC activity.
A stronger phenotype was observed in cells with downreg-
ulated catalytic subunit hNaa30p, as compared to knock-
down of auxiliary subunits hNaa35p and hNaa38p. Taken
together, these phenotypes suggest that hNatC is required
for normal cell growth and survival.
Furthermore, downregulation of hNatC subunits inde-
pendently of one another in colon carcinoma cell lines
HCT116 (TP53+/+ and TP53-/-) demonstrated association
between wild type TP53 and apoptosis: the observed
apoptotic phenotype was dependent on a functional TP53
[4]. In addition, our findings indicated an activation of
TP53 in cells with downregulated levels of hNaa30p. After
hNAA30 knockdown we observed an increase in p53 pro-
tein level, an increase in p53 Serine 37 phosphorylation,
and an increase in the expression of proapoptotic p53-
downstream genes KILLER, NOXA and FAS. It is unclear
how lack of hNatC-mediated acetylation causes activation
of TP53, and thereby expression of downstream proapop-
totic genes. One scenario may be that hNatC mediated
acetylation is needed for normal function of factors
upstream of p53. A summary of hNaa30p knockdown
phenotypes is given in Figure 4.
In zebrafish, the knockdown of the hNAA35 homologue
Embryonic Growth-Assiciated Factor (EGAP, zNAA35)
leads to embryonic lethality due to decreased cell prolifer-
ation, increased apoptosis, and poor blood vessel devel-
opment [55]. These findings emphasize the importance of
NatC for normal cell function and development in higher
eukaryotes. Further studies are needed to understand the
function of hNatC, and the mechanisms through which
hNatC knockdown phenotypes are mediated.
The human NatD and NatE complexes
In yeast, two more NATs, NatD and NatE, have been
described.
NatD
NatD is the N-acetyltransferase Naa40p (Nat4p). It was
recently described to acetylate the Ser- N-termini of his-
tones H2A and H4 in yeast [56]. No auxiliary subunits
have been presented. To our knowledge, no studies have
so far characterized the hNaa40p/hNatD activity in
human cells. However, based on homology predictions,
there exists a human homologue to the NAA40 gene [56].
hNatE
NatE is the designation for a complex consisting of the
putative N-acetyltransferase Naa50p (Nat5p), and
Naa10p and Naa15p of the NatA complex. hNaa50p is the
human homologue of the yeast Naa50p (Nat5p), and the
fruitfly San protein [24,57]. hNaa50p is predicted to be a
N-acetyltransferase, but this has not been verified exper-
imentally. Naa50p is physically associated with Naa10pBMC Proceedings 2009, 3(Suppl 6):S3 http://www.biomedcentral.com/1753-6561/3/S6/S3
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and Naa15p in several species including humans
[5,24,57], but knockdown of Naa50p does not affect NatA
type acetylations in lower eukaryotes. Thus, it is hypothe-
sized that Naa50p has functions distinct from those of the
NatA complex. However, the presence of Naa10p and
Naa15p may be obligatory for the stability of Naa50p in
yeast and humans [5,6,24]. In humans, knockdown of
hNAA50 resulted in less severe and more distinct pheno-
types as compared to hNatA (hNAA10-hNAA15) knock-
down, further suggesting that hNaa50p functions
separately from the hNatA complex [6]. More specifically,
studies from both fruitflies and humans suggest a role for
Naa50p in centromeric cohesion [6,57]. Proper sister
chromatid cohesion depends on the acetyltransferase
activity of hNaa50p, but this activity has so far not been
classified as a HAT or NAT activity [6]. Recently, Dro-
sophila Naa50p was also shown to have a more general
role in chromosome resolution [58]. So far, no substrate
of Naa50p from any species has been identified, thus the
final confirmation that this is indeed a NAT awaits further
investigations.
Summary and conclusion
The field of human NATs is still in its infant steps. During
the last five years the major NAT complexes hNatA,
hNatB, and hNatC have been described. This represents a
significant leap forward in the knowledge of N-terminal
acetylation. As to this date, the minor hNatD and hNatE
complexes remain unstudied. Bringing hNatD and hNatE
along will be important, especially hNatE (hNaa50p),
since this NAT type is completely uncharacterized for all
species with respect to substrate specificity. With the NatA
to NatE complexes characterized, it is likely that all NAT
types in lower eukaryotes are described, since all N-termi-
nally acetylated proteins are accounted for, and because
there are no additional genes in the S. cerevisiae genome
that are likely to encode additional NATs. However, for
humans and other higher eukaryotes it is not unlikely that
additional NATs exist. This is based on the fact that more
substrates are N-terminally acetylated in humans as com-
pared to yeast [9]. For example, Met-Lys N-termini are
unacetylated in yeast while a portion of these N-termini is
acetylated in human cells. Another area of uncertainty in
humans is the N-terminal acetylation of actins. These
acidic N-termini are acetylated, most likely post-transla-
tionally, by a so far unknown NAT. Finally, not all N-ter-
mini of Met-Ser, Met-Ala- types have their Met- cleaved by
MetAPs, and many of these N-termini are acetylated in
humans. These classes of substrates may indeed be N-ter-
minally acetylated by hNatA-hNatE activities. They may
also very well be acetylated by novel human NATs yet to
be described, like the Camello class of proteins present in
higher eukaryotes, which displays sequence similarity to
the NATs [7].
Even though knockdown phenotypes of all major human
NATs suggest important roles for these complexes, func-
tional links between specific substrates and the pheno-
types have not been established. Clearly, this represents
challenge of great importance. Recent works estimate that
Knockdown of hNAA30 of the hNatC complex leads to p53-dependent apoptosis Figure 4
Knockdown of hNAA30 of the hNatC complex leads to p53-dependent apoptosis. Knockdown of hNAA30 may lead 
to the reduced acetylation of hNaa30p substrates. As a direct or indirect effect of this, p53 is stabilized and phosphorylated on 
Serine 37, and subsequently, transcription of p53 downstream proapoptotic genes NOXA, KILLER and FAS is activated, resulting 
in apoptosis.
ML
ML
ML
x
y
z
M
Ribosome
hNaa35p
hNaa38p
L
p53
Ser37
P
Noxa Killer
Proteins with less
N-α−acetylation
Apoptosis genes
Fas
hNaa30p
Apoptosis
Direct or 
indirectBMC Proceedings 2009, 3(Suppl 6):S3 http://www.biomedcentral.com/1753-6561/3/S6/S3
Page 11 of 12
(page number not for citation purposes)
80% of all soluble human proteins are N-terminally
acetylated. The human NATs display severe knockdown
phenotypes, and have several potential links to disease.
Thus, this modification and these enzymes clearly deserve
significant attention in the future.
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